Name | Number of supported studies | Average coverage | |
---|---|---|---|
microglial cell | 10 studies | 29% ± 9% | |
GABAergic neuron | 9 studies | 50% ± 24% | |
pericyte | 9 studies | 22% ± 5% | |
glutamatergic neuron | 7 studies | 41% ± 22% | |
endothelial cell | 7 studies | 37% ± 18% | |
smooth muscle cell | 7 studies | 33% ± 10% | |
epithelial cell | 6 studies | 34% ± 25% | |
interneuron | 6 studies | 50% ± 26% | |
type II pneumocyte | 6 studies | 50% ± 13% | |
cardiac muscle cell | 5 studies | 58% ± 14% | |
Mueller cell | 5 studies | 67% ± 14% | |
astrocyte | 5 studies | 36% ± 17% | |
oligodendrocyte precursor cell | 5 studies | 29% ± 8% | |
type I pneumocyte | 5 studies | 49% ± 7% | |
plasma cell | 4 studies | 33% ± 10% | |
B cell | 4 studies | 25% ± 10% | |
mesothelial cell | 4 studies | 58% ± 16% | |
immature B cell | 3 studies | 24% ± 11% | |
retinal pigment epithelial cell | 3 studies | 60% ± 19% | |
ciliated cell | 3 studies | 22% ± 4% | |
granule cell | 3 studies | 30% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 96% | 1567.21 | 930 / 966 | 97% | 28.60 | 510 / 527 |
stomach | 76% | 983.96 | 274 / 359 | 98% | 28.78 | 279 / 286 |
pancreas | 96% | 458.51 | 316 / 328 | 76% | 9.19 | 135 / 178 |
adrenal gland | 99% | 1103.51 | 255 / 258 | 57% | 9.18 | 131 / 230 |
lung | 98% | 1361.21 | 566 / 578 | 55% | 6.50 | 640 / 1155 |
kidney | 97% | 692.10 | 86 / 89 | 42% | 3.42 | 374 / 901 |
brain | 89% | 1297.87 | 2353 / 2642 | 43% | 3.02 | 306 / 705 |
breast | 84% | 558.47 | 386 / 459 | 32% | 2.99 | 359 / 1118 |
uterus | 81% | 464.87 | 138 / 170 | 30% | 3.51 | 137 / 459 |
bladder | 62% | 268.24 | 13 / 21 | 36% | 8.52 | 180 / 504 |
blood vessel | 94% | 1010.77 | 1254 / 1335 | 0% | 0 | 0 / 0 |
heart | 92% | 1892.35 | 791 / 861 | 0% | 0 | 0 / 0 |
prostate | 69% | 318.92 | 169 / 245 | 18% | 0.86 | 89 / 502 |
adipose | 82% | 445.20 | 983 / 1204 | 0% | 0 | 0 / 0 |
spleen | 77% | 292.63 | 186 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 67% | 587.98 | 622 / 929 | 0% | 0 | 0 / 0 |
esophagus | 7% | 23.68 | 104 / 1445 | 52% | 15.82 | 95 / 183 |
skin | 34% | 149.97 | 608 / 1809 | 21% | 1.78 | 97 / 472 |
lymph node | 0% | 0 | 0 / 0 | 38% | 2.80 | 11 / 29 |
muscle | 38% | 126.15 | 304 / 803 | 0% | 0 | 0 / 0 |
thymus | 23% | 77.92 | 153 / 653 | 11% | 0.68 | 67 / 605 |
ovary | 17% | 64.01 | 30 / 180 | 13% | 0.86 | 56 / 430 |
eye | 0% | 0 | 0 / 0 | 25% | 1.52 | 20 / 80 |
tonsil | 0% | 0 | 0 / 0 | 13% | 2.91 | 6 / 45 |
liver | 0% | 0 | 0 / 226 | 3% | 0.26 | 11 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051896 | Biological process | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0046854 | Biological process | phosphatidylinositol phosphate biosynthetic process |
GO_0006661 | Biological process | phosphatidylinositol biosynthetic process |
GO_0012505 | Cellular component | endomembrane system |
GO_0005829 | Cellular component | cytosol |
GO_0001931 | Cellular component | uropod |
GO_0005886 | Cellular component | plasma membrane |
GO_0052742 | Molecular function | phosphatidylinositol kinase activity |
GO_0000285 | Molecular function | 1-phosphatidylinositol-3-phosphate 5-kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0016308 | Molecular function | 1-phosphatidylinositol-4-phosphate 5-kinase activity |
GO_0052810 | Molecular function | 1-phosphatidylinositol-5-kinase activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | PIP5K1B |
Protein name | Phosphatidylinositol-4-phosphate 5-kinase type 1 beta Phosphatidylinositol 4-phosphate 5-kinase type-1 beta (PIP5K1-beta) (PtdIns(4)P-5-kinase 1 beta) (EC 2.7.1.68) (Phosphatidylinositol 4-phosphate 5-kinase type I beta) (PIP5KIbeta) (Protein STM-7) (Type I phosphatidylinositol 4-phosphate 5-kinase beta) |
Synonyms | STM7 |
Description | FUNCTION: Catalyzes the phosphorylation of phosphatidylinositol 4-phosphate (PtdIns(4)P/PI4P) to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2/PIP2), a lipid second messenger that regulates several cellular processes such as signal transduction, vesicle trafficking, actin cytoskeleton dynamics, cell adhesion, and cell motility (By similarity). PtdIns(4,5)P2 can directly act as a second messenger or can be utilized as a precursor to generate other second messengers: inositol 1,4,5-trisphosphate (IP3), diacylglycerol (DAG) or phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3/PIP3) (By similarity). Mediates RAC1-dependent reorganization of actin filaments. Contributes to the activation of phospholipase PLD2. Together with PIP5K1A, is required, after stimulation by G-protein coupled receptors, for the synthesis of IP3 that will induce stable platelet adhesion (By similarity). . |
Accessions | A0A0A0MT25 ENST00000440050.5 ENST00000377284.5 A0A0A0MRU3 ENST00000265382.8 [O14986-1] ENST00000437200.5 A0A0A0MSP5 ENST00000478500.3 [O14986-2] O14986 ENST00000541509.5 [O14986-3] |